Literature DB >> 10632375

Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.

T Furui1, R LaPushin, M Mao, H Khan, S R Watt, M A Watt, Y Lu, X Fang, S Tsutsui, Z H Siddik, R C Bast, G B Mills.   

Abstract

Lysophosphatidic acid (LPA) is one of the major growth factors in ascites from ovarian cancer patients and appears to play an important role in proliferation, survival, and invasion of ovarian cancer cells. Recently, several groups have shown that Edg-2, which belongs to the G-protein coupled receptor family, is a functional LPA receptor. Northern blot analysis showed that most ovarian cancer cell lines express Edg-2. Edg-2 expression was especially high in the cisplatin-resistant and slowly proliferating 2780cp cell line and was almost absent from the cisplatin-sensitive and rapidly proliferating A2780 cell line. We thus assessed whether Edg-2 could contribute to changes in cell viability, cell proliferation, or cisplatin resistance. Stable overexpression of Edg-2 in A2780 cells induced an exogenous LPA-independent decrease in proliferation but did not alter cisplatin sensitivity. The LPA-independent decrease in growth rate induced by overexpression of Edg-2 could be explained, at least in part, by Edg-2-induced apoptosis rather than by effects on cell cycle progression. In agreement with the results in stably transfected A2780 cells, transient expression of Edg-2 in Jurkat T cells also induced apoptosis. When cells were separated from the extracellular matrix, they underwent a specialized form of apoptosis called anoikis, which is particularly important in survival of cells in the circulation during metastasis. A2780 cells engineered to overexpress Edg-2 were particularly sensitive to anoikis. These observations suggest that Edg-2 may be a negative regulator for ovarian epithelial cell growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632375

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.

Authors:  Tugan Bese; Merve Barbaros; Elif Baykara; Onur Guralp; Salih Cengiz; Fuat Demirkiran; Cevdet Sanioglu; Macit Arvas
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells.

Authors:  Megumu Tsujino; Minako Fujii; Kyoko Okabe; Toshio Mori; Nobuyuki Fukushima; Toshifumi Tsujiuchi
Journal:  Virchows Arch       Date:  2010-10-03       Impact factor: 4.064

3.  Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor.

Authors:  Natalie Fisher; Timothy Hilton-Bolt; Michael G Edwards; Katherine J Haxton; Michael McKenzie; Steven M Allin; Alan Richardson
Journal:  ACS Med Chem Lett       Date:  2013-11-18       Impact factor: 4.345

4.  Negative regulation of cell motile and invasive activities by lysophosphatidic acid receptor-3 in colon cancer HCT116 cells.

Authors:  Rie Fukui; Eriko Tanabe; Misaho Kitayoshi; Kyohei Yoshikawa; Nobuyuki Fukushima; Toshifumi Tsujiuchi
Journal:  Tumour Biol       Date:  2012-07-05

5.  The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury.

Authors:  Manuela Funke; Zhenwen Zhao; Yan Xu; Jerold Chun; Andrew M Tager
Journal:  Am J Respir Cell Mol Biol       Date:  2011-10-20       Impact factor: 6.914

6.  Matrix-Assisted Laser Desorption Ionization Mapping of Lysophosphatidic Acid Changes after Traumatic Brain Injury and the Relationship to Cellular Pathology.

Authors:  Whitney S McDonald; Elizabeth E Jones; Jonathan M Wojciak; Richard R Drake; Roger A Sabbadini; Neil G Harris
Journal:  Am J Pathol       Date:  2018-07-16       Impact factor: 4.307

7.  Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.

Authors:  Gyöngyi N Kiss; James I Fells; Renuka Gupte; Sue-Chin Lee; Jianxiong Liu; Nóra Nusser; Keng G Lim; Ramesh M Ray; Fang-Tsyr Lin; Abby L Parrill; Balázs Sümegi; Duane D Miller; Gabor Tigyi
Journal:  Mol Pharmacol       Date:  2012-09-11       Impact factor: 4.436

Review 8.  Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.

Authors:  Mandi M Murph; Giang H Nguyen; Harish Radhakrishna; Gordon B Mills
Journal:  Biochim Biophys Acta       Date:  2008-04-29

9.  Mitigation of radiation injury by selective stimulation of the LPA(2) receptor.

Authors:  Gyöngyi N Kiss; Sue-Chin Lee; James I Fells; Jianxiong Liu; William J Valentine; Yuko Fujiwara; Karin Emmons Thompson; Charles R Yates; Balázs Sümegi; Gabor Tigyi
Journal:  Biochim Biophys Acta       Date:  2013-01

Review 10.  Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.

Authors:  M T M van Jaarsveld; J M Houthuijzen; E E Voest
Journal:  Oncogene       Date:  2015-12-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.